Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 29 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 15 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

At Rs 28.79, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 2.84% on 15 Jul 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 28.27, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 3.38% on 9 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 01 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

At Rs 29.58, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 5% on 15 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 08 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

At Rs 28.46, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price.

Mangalam Drugs and Organics Ltd. reported a devastating fourth quarter for FY26, with net losses widening to ₹13.42 crores—marking a staggering 22,466.67% year-on-year deterioration from a marginal profit of ₹0.06 crores in Q4 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹48.00 crores, saw its stock languish at ₹30.01 on May 15, down 62.74% over the past year and trading 68.34% below its 52-week high of ₹94.80.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

At Rs 31.57, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.99% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 02 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

At Rs 28.50, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 5% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.